DE69841273D1 - Verfahren zur identifikation von bindestellendomänen, die ihre epitopbindefähigkeit beibehalten - Google Patents

Verfahren zur identifikation von bindestellendomänen, die ihre epitopbindefähigkeit beibehalten

Info

Publication number
DE69841273D1
DE69841273D1 DE69841273T DE69841273T DE69841273D1 DE 69841273 D1 DE69841273 D1 DE 69841273D1 DE 69841273 T DE69841273 T DE 69841273T DE 69841273 T DE69841273 T DE 69841273T DE 69841273 D1 DE69841273 D1 DE 69841273D1
Authority
DE
Germany
Prior art keywords
epitophineness
keep
ability
binding domains
identifying binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69841273T
Other languages
English (en)
Inventor
Peter Kufer
Tobias Raum
Katrin Borschert
Florian Zettl
Ralf Lutterbuese
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Research Munich GmbH
Original Assignee
Micromet GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Micromet GmbH filed Critical Micromet GmbH
Application granted granted Critical
Publication of DE69841273D1 publication Critical patent/DE69841273D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70525—ICAM molecules, e.g. CD50, CD54, CD102
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70528—CD58
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE69841273T 1997-11-17 1998-11-16 Verfahren zur identifikation von bindestellendomänen, die ihre epitopbindefähigkeit beibehalten Expired - Lifetime DE69841273D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP97120096 1997-11-17
PCT/EP1998/007313 WO1999025818A1 (en) 1997-11-17 1998-11-16 Method of identifying binding site domains that retain the capacity of binding to an epitope

Publications (1)

Publication Number Publication Date
DE69841273D1 true DE69841273D1 (de) 2009-12-17

Family

ID=8227629

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69841273T Expired - Lifetime DE69841273D1 (de) 1997-11-17 1998-11-16 Verfahren zur identifikation von bindestellendomänen, die ihre epitopbindefähigkeit beibehalten

Country Status (13)

Country Link
US (1) US7435549B1 (de)
EP (1) EP1032660B1 (de)
JP (2) JP4327350B2 (de)
AT (1) ATE447613T1 (de)
AU (1) AU1873199A (de)
CA (1) CA2309679C (de)
CY (1) CY1110699T1 (de)
DE (1) DE69841273D1 (de)
DK (1) DK1032660T3 (de)
ES (1) ES2334184T3 (de)
HK (1) HK1031740A1 (de)
PT (1) PT1032660E (de)
WO (1) WO1999025818A1 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6420110B1 (en) * 1998-10-19 2002-07-16 Gpc Biotech, Inc. Methods and reagents for isolating biologically active peptides
GB9917027D0 (en) * 1999-07-20 1999-09-22 Affibody Technology Sweeden Ab In vitro selection and optional identification of polypeptides using solid support carriers
CZ20023203A3 (cs) * 2000-03-24 2003-08-13 Micromet Ag Multifunkční polypeptidy obsahující vazebné místo k epitopu receptorového komplexu NKG2D
US20020137022A1 (en) * 2000-08-02 2002-09-26 Min Li Methods and compositions for the construction and use of envelope viruses as display particles
NZ543202A (en) 2003-05-31 2008-04-30 Micromet Ag Pharmaceutical composition comprising a bispecific antibody for epcam
SI1673398T1 (sl) 2003-10-16 2011-05-31 Micromet Ag Multispecifiäśne deimunizirajoäśe cd3 povezovalne molekule
CA2671264C (en) 2006-11-30 2015-11-24 Research Development Foundation Improved immunoglobulin libraries
TWI653333B (zh) 2010-04-01 2019-03-11 安進研究（慕尼黑）有限責任公司 跨物種專一性之ＰＳＭＡｘＣＤ３雙專一性單鏈抗體
US9255595B2 (en) * 2011-04-29 2016-02-09 Bae Systems Information And Electronic Systems Integration Inc. Optical dome bezel
CA2881966C (en) 2012-08-24 2020-10-06 The Regents Of The University Of California Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis
JP6502931B2 (ja) 2013-10-11 2019-04-17 アメリカ合衆国 Ｔｅｍ８抗体およびその使用
WO2015103549A1 (en) 2014-01-03 2015-07-09 The United States Of America, As Represented By The Secretary Department Of Health And Human Services Neutralizing antibodies to hiv-1 env and their use
EP3218397B8 (de) 2014-11-14 2021-04-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralisierende antikörper gegen ebola virus glykoprotein und deren verwendung
US10301377B2 (en) 2015-02-24 2019-05-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Middle east respiratory syndrome coronavirus immunogens, antibodies, and their use
LT3271389T (lt) 2015-03-20 2020-05-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizuojantys antikūnai prieš gp120 ir jų panaudojimas
US10392441B2 (en) 2015-10-07 2019-08-27 United States Of America, As Represented By The Secretary, Department Of Health And Human Services IL-7R-alpha specific antibodies for treating acute lymphoblastic leukemia
CA3003878A1 (en) 2015-11-03 2017-05-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to hiv-1 gp41 and their use
WO2017192589A1 (en) 2016-05-02 2017-11-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to influenza ha and their use and identification
CA3029003A1 (en) 2016-06-27 2018-01-04 The Regents Of The University Of California Cancer treatment combinations
EP3580235B1 (de) 2017-02-10 2024-05-01 The United States of America, as represented by the Secretary, Department of Health and Human Services Neutralisierende antikörper gegen das plasmodium-falciparum-circumsporozoit-protein und verwendung davon
WO2019136029A1 (en) 2018-01-02 2019-07-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to ebola virus glycoprotein and their use
AU2019226034A1 (en) 2018-02-21 2020-10-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to HIV-1 Env and their use
EP3883609A2 (de) 2018-12-20 2021-09-29 The United States of America, as represented by the Secretary, Department of Health and Human Services Glykoprotein-spezifische monoklonale antikörper des ebola-virus und deren verwendungen
WO2020227228A2 (en) 2019-05-03 2020-11-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
US20230085439A1 (en) 2019-05-21 2023-03-16 University Of Georgia Research Foundation, Inc. Antibodies that bind human metapneumovirus fusion protein and their use
EP3994173A1 (de) 2019-07-02 2022-05-11 The United States of America, as represented by the Secretary, Department of Health and Human Services Monoklonale egfrviii-bindende antikörper und ihre verwendung
KR20230098334A (ko) 2020-11-06 2023-07-03 암젠 리서치 (뮌헨) 게엠베하 Cldn6 및 cd3에 선택적으로 결합하는 폴리펩디드 작제물
WO2022132904A1 (en) 2020-12-17 2022-06-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies targeting sars-cov-2
AU2021414400A1 (en) 2020-12-31 2023-08-17 Innate Pharma Multifunctional natural killer (nk) cell engagers binding to nkp46 and cd123
CA3210753A1 (en) 2021-02-09 2022-08-18 University Of Georgia Research Foundation, Inc. Human monoclonal antibodies against pneumococcal antigens
IL304955A (en) 2021-02-09 2023-10-01 Us Health Antibodies targeting the spike protein of a coronavirus
AU2022345251A1 (en) 2021-09-17 2024-03-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Synthetic humanized llama nanobody library and use thereof to identify sars-cov-2 neutralizing antibodies
WO2023154824A1 (en) 2022-02-10 2023-08-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies that broadly target coronaviruses
WO2023192881A1 (en) 2022-03-28 2023-10-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to hiv-1 env and their use
WO2024030829A1 (en) 2022-08-01 2024-02-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies that bind to the underside of influenza viral neuraminidase
WO2024054822A1 (en) 2022-09-07 2024-03-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Engineered sars-cov-2 antibodies with increased neutralization breadth
WO2024064826A1 (en) 2022-09-22 2024-03-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
IE921169A1 (en) * 1991-04-10 1992-10-21 Scripps Research Inst Heterodimeric receptor libraries using phagemids
US5637481A (en) * 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
ES2168277T3 (es) * 1992-09-04 2002-06-16 Scripps Research Inst Fagemidos que coexpresan un receptor de superficie y una proteina heterologa de superficie.
AU690528B2 (en) * 1992-12-04 1998-04-30 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
HU221001B1 (hu) 1994-03-17 2002-07-29 Merck Patent Gmbh. Egyláncú anti-EGFR Fv-k és anti-EGFR ellenanyagok
GB9500851D0 (en) * 1995-01-17 1995-03-08 Bionvent International Ab Method of selecting specific bacteriophages
ATE218143T1 (de) * 1996-09-03 2002-06-15 Gsf Forschungszentrum Umwelt Verwendung bi-und trispezifischer antikörper zur induktion einer tumorimmunität
JP2002501721A (ja) * 1997-08-01 2002-01-22 モルフォシス・アクチェンゲゼルシャフト 多量体（ポリ）ペプチドコンプレックスのメンバーをコードする核酸配列を同定するための新規方法およびファージ

Also Published As

Publication number Publication date
DK1032660T3 (da) 2010-01-18
JP4327350B2 (ja) 2009-09-09
ES2334184T3 (es) 2010-03-05
AU1873199A (en) 1999-06-07
JP4977156B2 (ja) 2012-07-18
JP2002508924A (ja) 2002-03-26
EP1032660A1 (de) 2000-09-06
HK1031740A1 (en) 2001-06-22
EP1032660B1 (de) 2009-11-04
PT1032660E (pt) 2009-12-28
CY1110699T1 (el) 2015-06-10
ATE447613T1 (de) 2009-11-15
CA2309679A1 (en) 1999-05-27
WO1999025818A1 (en) 1999-05-27
JP2009148280A (ja) 2009-07-09
CA2309679C (en) 2010-07-20
US7435549B1 (en) 2008-10-14

Similar Documents

Publication Publication Date Title
DE69841273D1 (de) Verfahren zur identifikation von bindestellendomänen, die ihre epitopbindefähigkeit beibehalten
DE69718341D1 (de) Verfahren und mittel zur auswahl von peptiden und proteinen mit spezifischer affinität zu einem zielmolekül
WO2004065416A3 (en) Synthetic antibody phage libraries
EP2141243A3 (de) Proteingerüste für Antikörpermimetika und andere Bindungsproteine
DE69534588D1 (de) Protocadherin-proteine und verwendungen davon
DK0758383T3 (da) Oplöselige polypeptidfraktioner af LAG-3-proteinet; fremgangsmåde til fremstilling; terapeutisk sammensætning; antiidiotypisk antistof
ATE352618T1 (de) Rezeptor 5, der eine für den zelltod verantwortliche domäne enthält
EP1140175A4 (de) Antikörper gegen verkürzten vegf-d und deren verwendungen
ATE372382T1 (de) Ein faktor viii-polypeptid mit faktor viii:c- aktivität
ATE172247T1 (de) Car-rezeptoren und verwandte moleküle und entsprechende methoden
DE69333382D1 (de) Hyaluronan rezeptor (rezeptor durch hyaluronan verurzachte bewelichkeit) und hyaluronan bindende peptide
DK0901526T3 (da) Cortistatin: neuropeptider, sammensætninger og metoder
WO1994026891A3 (en) Purified mammalian flt3 ligands and agonists and antagonists thereof
EP2305710A3 (de) Synthetische Antikörperphagenbibliotheken
WO2004094615A3 (en) Prokaryotic collagen-like proteins and uses thereof
EP0643728A4 (de) Dem interzellulär-adhäsions-molekül (icam) ähnliche proteine.
CA2218755A1 (en) Monoclonal antibody to human beta 2 integrin alpha subunit
WO1998002557A3 (en) MAMMALIAN TNF-α CONVERTASES
ATE379967T1 (de) Nukleinsäuren kodierend miteinander verbundene chromo/fluoreszenzdomänen und verfahren zu ihrer verwendung
WO2000017363A3 (en) Interleukin-1 like molecule: interleukin-1-zeta; nucleic acids, polypeptides, antibodies, their uses
DE69716106D1 (de) Trennung von proteinen durch kapillarelektrophorese mit aminosäure enthaltenden puffern
ATE417105T1 (de) Spleissvariante des kopftrauma induzierten zytoplasmatischen calcium-bindenden proteins

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
R082 Change of representative

Ref document number: 1032660

Country of ref document: EP

Representative=s name: KOCH & SCHIWECK PATENTANWAELTE, 80339 MUENCHEN, DE

R082 Change of representative

Ref document number: 1032660

Country of ref document: EP

Representative=s name: KOCH & SCHIWECK GBR PATENTANWAELTE, DE

R081 Change of applicant/patentee

Ref document number: 1032660

Country of ref document: EP

Owner name: AMGEN RESEARCH (MUNICH) GMBH, DE

Free format text: FORMER OWNER: MICROMET AG, 81477 MUENCHEN, DE

Effective date: 20120727

R082 Change of representative

Ref document number: 1032660

Country of ref document: EP

Representative=s name: KOCH & SCHIWECK GBR PATENTANWAELTE, DE

Effective date: 20120727